SALSA MLPA P476 ZNRF3 probemixnew

application: Adrenocortical tumours and other solid tumours
region: ZNRF3, 22q12.1
[login for my products]
version: A1

item no. description price
P476-025R SALSA MLPA P476 ZNRF3 probemix – 25 rxn € 237
P476-050R SALSA MLPA P476 ZNRF3 probemix – 50 rxn € 474
P476-100R SALSA MLPA P476 ZNRF3 probemix – 100 rxn € 948
EK1-FAM SALSA MLPA EK1 reagent kit – 100 rxn - FAM € 294
EK1-Cy5 SALSA MLPA EK1 reagent kit – 100 rxn - Cy5 € 294
EK5-FAM SALSA MLPA EK5 reagent kit – 500 rxn - FAM € 1355
EK5-Cy5 SALSA MLPA EK5 reagent kit – 500 rxn - Cy5 € 1355

Please note that both a probemix and reagent kit are needed to perform MLPA.

description
General information: The SALSA MLPA Probemix P476 ZNRF3 is a research use only (RUO) assay for the detection of deletions and duplications in the ZNRF3 gene.

ZNRF3 is an E3 ubiquitin-protein ligase that acts as a negative feedback regulator of Wnt signalling (Hao et al. 2012). Three independent studies show homozygous deletions of the ZNRF3 gene in 10 to 16% of adrenocortical carcinoma cases (Assié et al. 2014; Juhlin et al. 2015; Zheng et al. 2016). Moreover, in 51% of microsatellite stable colorectal cancers deletion events at the ZNRF3 locus are detected (Bond et al. 2016). Deletions of the ZNRF3 gene are also found in osteoblastoma and prostate cancer (Nord et al. 2013; Robinson et al. 2015).

Probemix content: The SALSA MLPA Probemix P476-A1 ZNRF3 contains 42 MLPA probes with amplification products between 130 and 433 nucleotides (nt). This includes 15 probes for the ZNRF3 gene, plus four flanking probes for upstream genes and five flanking probes for downstream genes. In addition, 18 reference probes are included and target relatively copy number stable regions in various cancer types including adrenocortical carcinoma, colorectal cancer and prostate adenocarcinoma. Complete probe sequences and the identity of the genes detected by the reference probes is available in Table 2b of the product description and online (www.mlpa.com).

This probemix contains nine quality control fragments generating amplification products between 64 and 105 nt: four DNA Quantity Fragments (Q-fragments), two DNA Denaturation Fragments (D-fragments), one Benchmark fragment, and one chromosome X and one chromosome Y-specific fragment. More information on how to interpret observations on these control fragments can be found in the MLPA General Protocol and online at www.mlpa.com.

product history
version A1: changes not specified
new products
P476-ZNRF3
Adrenocortical tumours and other solid tumours
improved products
P175-Tumour Gain
Tumour Gain
P260-PALB2-RAD50-RAD51C-RAD51D
Hereditary predisposition to Cancer
P103-DPYD
Dihydropyrimidine dehydrogenase (DPYD) deficiency
P152-ABCA4 mix-2
Stargardt, Macular dystrophy, Retinitis pigmentosa, age-related macular degeneration, cone rod dystrophies
P151-ABCA4 mix-1
Stargardt, Macular dystrophy, Retinitis pigmentosa, age-related macular degeneration, cone rod dystrophies
P267-Dandy-Walker
Dandy-Walker Malformation (DWM)
P226-SDH
Paragangliomas (PGL)
P335-ALL-IKZF1
ALL
P340-EHMT1
9q subtelomeric deletion syndrome (9qSTDS) or Kleefstra syndrome.
Newsletter  |  Home  |  Site map  |  Terms and Conditions  |  Search  |  Copyright © 2018 MRC-Holland